Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed

Immunological Reviews

Volumn 222, Issue 1, 2008, Pages 299-315

  Ten Hagen, Timo L M ^a   Seynhaeve, Ann L B ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Solid tumor; Tumor necrosis factor ; Vasculature

Indexed keywords

BACTERIAL VACCINE; CISPLATIN; COLEY'S TOXIN; DOXORUBICIN; FOTEMUSTINE; GEMCITABINE; HISTAMINE; INTERLEUKIN 2; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE; VASOACTIVE AGENT;

CACHEXIA; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SERRATIA MARCESCENS; SHOCK; SOLID TUMOR; STREPTOCOCCUS PYOGENES; TISSUE PRESSURE; TUMOR CELL; TUMOR VASCULARIZATION; VASOPLEGIA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPILLARY PERMEABILITY; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTORS; VASOCONSTRICTOR AGENTS;

EID: 41149083660     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00619.x     Document Type: Review

References (185)

1. Baxter LT, Jain RK. Vascular permeability and interstitial diffusion in superfused tissues: a two-dimensional model. Microvasc Res 1988 36 : 108 115.
2. Yuan F, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995 55 : 3752 3756.
3. Yuan F, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994 54 : 3352 3356.
4. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988 133 : 95 109.
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005 307 : 58 62.
6. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989 81 : 570 576.
7. Leunig M, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174 T in SCID mice. Cancer Res 1992 52 : 6553 6560.
8. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996 74 : 533 536.
9. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995 55 : 5451 5458.
10. Salnikov AV, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 2003 17 : 1756 1758.
11. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst 2002 94 : 417 421.
12. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res 1990 40 : 246 263.
13. Padera TP, Stoll BR, So PT, Jain RK. Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions. Mol Imaging 2002 1 : 9 15.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 285 : 1182 1186.
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 1 : 27 31.
16. O'Reilly MS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997 88 : 277 285.
17. O'Reilly MS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994 79 : 315 328.
18. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000 52 : 237 268.
19. Davis PD, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002 62 : 7247 7253.
20. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005 5 : 423 435.
21. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs 2006 7 : 522 528.
22. Tong RT, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004 64 : 3731 3736.
23. ten Hagen TL, Eggermont AM. Solid tumor therapy: manipulation of the vasculature with TNF. Technol Cancer Res Treat 2003 2 : 195 203.
24. ten Hagen TL, Eggermont AM. Manipulation of the tumour-associated vasculature to improve tumour therapy. J Liposome Res 2002 12 : 149 154.
25. Willett CG, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 10 : 145 147.
26. Azizi AA, et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006 7 : 521 523.
27. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005 69 : 46 56.
28. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 2342.
29. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005 69 : 4 10.
30. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 9 : 669 676.
31. Pal S, et al. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc Res 2000 60 : 112 120.
32. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995 146 : 1029 1039.
33. Nagy JA, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002 196 : 1497 1506.
34. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003 42 : 419 436.
35. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988 85 : 6949 6953.
36. Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 1989 981 : 27 35.
37. Seynhaeve AL, Vermeulen CE, Eggermont AM, ten Hagen TL. Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells. Cell Biochem Biophys 2006 44 : 157 169.
38. Brunstein F, et al. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004 96 : 1603 1610.
39. Nooijen PTGA, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996 74 : 1908 1915.
40. Seynhaeve AL, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007 67 : 9455 9462.
41. Benckhuijsen C, Varossieau FJ, Hart AA, Wieberdink J, Noordhoek J. Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 1986 237 : 583 588.
42. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997 54 : 8 14.
43. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997 54 : 15 21.
44. Gabizon A, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994 54 : 987 992.
45. Coley WB. The therapeutic value of the mixed toxins of the streptococcus of erysipelas and bacillus prodigious in the treatment of inoperable malignant tumors. Am J Med Sci 1896 112 : 251 281.
46. Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003 79 : 672 680.
47. O'Malley WE, Achinstein B, Shear MJ. Action of bacterial polysaccharide on tumor III. Repeated response of sarcoma 37, in tolerant mice, to Serratia marcescens endotoxin. Cancer Res 1963 23 : 890 895.
48. Carswell EA, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975 72 : 3666 3670.
49. Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 1985 313 : 803 806.
50. Wang AM, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985 228 : 149 154.
51. Lenk H, Tanneberger S, Muller U, Ebert J, Shiga T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989 24 : 391 392.
52. Aulitzky WE, et al. Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a Phase I trial. Eur J Cancer 1991 27 : 462 467.
53. Kimura K, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987 20 : 223 229.
54. Spriggs DR, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988 80 : 1039 1044.
55. Wiedenmann B, et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic varcinomas. J Cancer Res Clin Oncol 1989 115 : 189 192.
56. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992 10 : 52 60.
57. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose RTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992 16 : 234 240.
58. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996 16 : 1 11.
59. van Horssen R, ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006 11 : 397 408.
60. Wullaert A, Heyninck K, Beyaert R. Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol 2006 72 : 1090 1101.
61. Manda T, et al. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity. Cancer Res 1987 47 : 3707 3711.
62. McIntosh JK, Mule JJ, Travis WD, Rosenberg SA. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. Cancer Res 1990 50 : 2463 2469.
63. Stoelcker B, et al. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000 156 : 1171 1176.
64. Ferrero E, et al. Roles of tumor necrosis factor P55 and P75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol Cell Physiol 2001 281 : C1173 C1179.
65. van Horssen R, et al. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. Int J Cancer 2006 119 : 1481 1490.
66. Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958 148 : 616 632.
67. Krementz ET, et al. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994 220 : 520 534.
68. Grunhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006 3 : 94 103.
69. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977 185 : 555 564.
70. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987 60 : 1703 1707.
71. Grunhagen DJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006 106 : 1776 1784.
72. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003 4 : 429 437.
73. Eggermont AMM, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996 14 : 2653 2665.
74. Eggermont AMM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 Patients with locally advanced soft tissue extremity sarcomas. The Cumulative Multicenter European Experience. Ann Surg 1996 224 : 756 764.
75. Manusama ER, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996 83 : 551 555.
76. Manusama ER, Stavast J, Durante NMC, Marquet RL, Eggermont AMM. Isolated limb perfusion sith TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996 22 : 152 157.
77. de Wilt JHW, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999 80 : 161 166.
78. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007 99 : 1441 1454.
79. Lienard D, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-apha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994 4 : 21 26.
80. Olieman AF, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999 134 : 303 307.
81. Vaglini M, et al. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994 4 : 35 38.
82. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996 14 : 479 489.
83. Salmon SE, Young L, Scuderi P, Clark B. Antineoplastic effects of tumor necrosis factor alone and in combination with gamma-interferon on tumor biopsies in clonogenic assay. J Clin Oncol 1987 5 : 1816 1821.
84. Schiller JH, Bittner G, Storer B, Willson JK. Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines. Cancer Res 1987 47 : 2809 2813.
85. Manusama ER, de Wilt JH, ten Hagen TL, Marquet RL, Eggermont AM. Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep 1999 6 : 173 177.
86. Seynhaeve AL, de Wilt JH, van Tiel ST, Eggermont AM, ten Hagen TL. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer 2002 86 : 1174 1179.
87. de Wilt JH, et al. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer 2000 83 : 1176 1182.
88. Eggermont AMM, Schraffordt Koops H, Lienard D, Lejeune FJ, Oudkerk M. Angiographic observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas. Eur J Surg Oncol 1994 20 : 323.
89. Olieman AFT, et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997 4 : 64 69.
90. Weksler B, et al. Isolated single-lung perfusion with TNF-alpha in a rat sarcoma lung metastases model. Ann Thorac Surg 1994 58 : 328 331.
91. van der Veen AH, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000 82 : 973 980.
92. de Wilt JH, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000 82 : 1000 1003.
93. van Etten B, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 2003 88 : 314 319.
94. ten Hagen TL, et al. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000 87 : 829 837.
95. Van Ijken MG, et al. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 2000 23 : 449 455.
96. ten Hagen TLM, Eggermont AMM, Lejeune FJ. TNF is here to stay - revisited. Trends Immunol 2001 22 : 127 129.
97. Brouckaert P, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered doxil pharmacokinetics. Int J Cancer 2004 109 : 442 448.
98. Soma G, et al. Improvement of cytotoxicity of tumor necrosis factor (TNF) by increase in basicity of its N-terminal region. Biochem Biophys Res Commun 1987 148 : 629 635.
99. Van Ostade X, et al. Human TNF mutants with selective activity on the P55 receptor. Nature 1993 361 : 266 269.
100. Kuroda K, et al. Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int J Cancer 1995 63 : 152 157.
101. Tsutsumi Y, et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer 1995 71 : 963 968.
102. Lucas R, et al. Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity. Infect Immun 1997 65 : 2006 2010.
103. Gatanaga T, et al. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (RTNF-S) with less toxicity than conventional RTNF-alpha in vivo. J Biol Response Mod 1989 8 : 278 286.
104. Kaneda Y, et al. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice. Cancer Res 1998 58 : 290 295.
105. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 1993 268 : 26350 26357.
106. Soma GI, et al. Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. J Biol Response Mod 1988 7 : 587 595.
107. Lodato RF, Feig B, Akimaru K, Soma G, Klostergaard J. Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-alpha, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model. J Immunother Emphasis Tumor Immunol 1995 17 : 19 29.
108. Akimaru K, et al. Formulation and antitumor efficacy of liposomal-caprylated-TNF-SAM2. Cytokines Mol Ther 1995 1 : 197 210.
109. de Wilt JH, et al. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats. Anticancer Res 2000 20 : 3491 3496.
110. Curnis F, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000 18 : 1185 1190.
111. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002 110 : 475 482.
112. Colombo G, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 2002 277 : 47891 47897.
113. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci 2004 1028 : 104 112.
114. Sacchi A, et al. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 2006 12 : 175 182.
115. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 2004 64 : 7150 7155.
116. van Laarhoven HW, et al. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs 2005 24 : 27 36.
117. Tarli L, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999 94 : 192 198.
118. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001 28 : 534 539.
119. Borsi L, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002 102 : 75 85.
120. Carnemolla B, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002 99 : 1659 1665.
121. Borsi L, et al. Selective targeted delivery of TNF alpha to tumor blood vessels. Blood 2003 102 : 4384 4392.
122. Halin C, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003 63 : 3202 3210.
123. Balza E, et al. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 2006 12 : 2575 2582.
124. Tsunoda S, et al. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent. J Pharmacol Exp Ther 1999 290 : 368 372.
125. Kamada H, et al. Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha. Biochem Biophys Res Commun 1999 257 : 448 453.
126. Tsutsumi Y, et al. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. Br J Cancer 1996 74 : 1090 1095.
127. Kamada H, et al. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res 2000 60 : 6416 6420.
128. Shibata H, et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004 10 : 8293 8300.
129. Farma JM, et al. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer 2007 120 : 2474 2480.
130. van der Veen AH, Eggermont AM, Seynhaeve AL, van Tiel ST, ten Hagen TL. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer 1998 77 : 901 906.
131. ten Hagen TL, Seynhaeve AL, van Tiel ST, Ruiter DJ, Eggermont AM. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-rearing rats. Int J Cancer 2002 97 : 115 120.
132. Hoving S, Seynhaeve AL, van Tiel ST, Eggermont AM, ten Hagen TL. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats. Anticancer Drugs 2005 16 : 667 674.
133. Hoving S, van Tiel ST, Eggermont AM, ten Hagen TL. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats. Anticancer Res 2005 25 : 743 750.
134. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976 193 : 1007 1008.
135. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 2002 51 : 492 498.
136. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002 29 : 12 17.
137. Rosenberg SA. Interleukin 2 for patients with renal cancer. Nat Clin Pract Oncol 2007 4 : 497.
138. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000 6 : S55 S57.
139. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003 95 : 741 749.
140. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991 9 : 694 704.
141. Winkelhake JL, Gauny SS. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev 1990 42 : 1 28.
142. Hoving S, et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005 65 : 4300 4308.
143. Barger G, Dale HH. Chemical structure and sympathomimetic action of amines. J Physiol 1910 41 : 19 59.
144. Dale HH, Laidlaw PP. The physiological action of beta- iminazolylethylamine. J Physiol 1910 41 : 318 344.
145. Schild HO. The multiple facets of histamine research. Agents Actions 1981 11 : 12 19.
146. Jutel M, Blaser K, Akdis CA. The role of histamine in regulation of immune responses. Chem Immunol Allergy 2006 91 : 174 187.
147. Jutel M, Watanabe T, Akdis M, Blaser K, Akdis CA. Immune regulation by histamine. Curr Opin Immunol 2002 14 : 735 740.
148. Wang J, et al. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage Pool. J Biol Chem 2003 278 : 21751 21760.
149. Garrison JC. Histamine, Bradykinin, 5-Hydroxytryptamine and their Antagonists, 8th edn. New York : Pergamon Press, 1990 : 575 599.
150. Wu NZ, Baldwin AL. Transient venular permeability increase and endothelial gap formation induced by histamine. Am J Physiol 1992 262 : H1238 H1247.
151. Wu NZ, Baldwin AL. Possible mechanism(s) for permeability recovery of venules during histamine application. Microvasc Res 1992 44 : 334 352.
152. Carson MR, Shasby SS, Shasby DM. Histamine and inositol phosphate accumulation in endothelium: cAMP and a G protein. Am J Physiol 1989 257 : L259 L264.
153. Rotrosen D, Gallin JI. Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin, and promotes albumin diffusion across cultured endothelial monolayers. J Cell Biol 1986 103 : 2379 2387.
154. Joris I, Majno G, Ryan GB. Endothelial contraction in vivo: a study of the rat mesentery. Virchows Arch B Cell Pathol 1972 12 : 73 83.
155. Majno G, Palade GE. Studies on inflammation. 1. The effect of histamine and serotonin on vascular permeability: an electron microscopic study. J Biophys Biochem Cytol 1961 11 : 571 605.
156. Horan KL, Adamski SW, Ayele W, Langone JJ, Grega GJ. Evidence that prolonged histamine suffusions produce transient increases in vascular permeability subsequent to the formation of venular macromolecular leakage sites. Proof of the Majno-Palade hypothesis. Am J Pathol 1986 123 : 570 576.
157. Stelzner TJ, Weil JV, O'Brien RF. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J Cell Physiol 1989 139 : 157 166.
158. Resink TJ, Grigorian GY, Moldabaeva AK, Danilov SM, Buhler FR. Histamine-induced phosphoinositide metabolism in cultured human umbilical vein endothelial cells. Association with thromboxane and prostacyclin release. Biochem Biophys Res Commun 1987 144 : 438 446.
159. Ehringer WD, Edwards MJ, Miller FN. Mechanisms of alpha-thrombin, histamine, and bradykinin induced endothelial permeability. J Cell Physiol 1996 167 : 562 569.
160. Stevens T, Garcia JG, Shasby DM, Bhattacharya J, Malik AB. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung Cell Mol Physiol 2000 279 : L419 L422.
161. Brunstein F, Rens J, van Tiel ST, Eggermont AM, ten Hagen TL. Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery. Br J Cancer 2006 95 : 1663 1669.
162. Brunstein F, et al. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Ann Surg Oncol 2007 14 : 795 801.
163. Nooijen PTGA, et al. Transient induction of E-selectin expression following TNF alpha- based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother Emphasis Tumor Immunol 1996 19 : 33 44.
164. Yang L, et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 2005 106 : 584 592.
165. Vanhee D, et al. Modulation of endothelial cell adhesion molecule expression in a situation of chronic inflammatory stimulation. Cell Immunol 1994 155 : 446 456.
166. VandenBerg E, Reid MD, Edwards JD, Davis HW. The role of the cytoskeleton in cellular adhesion molecule expression in tumor necrosis factor-stimulated endothelial cells. J Cell Biochem 2004 91 : 926 937.
167. Imaizumi T, et al. Expression of tumor necrosis factor-alpha in cultured human endothelial cells stimulated with lipopolysaccharide or interleukin-1alpha. Arterioscler Thromb Vasc Biol 2000 20 : 410 415.
168. Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol 2001 47 : 661 673.
169. Gutman M, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997 79 : 1129 1137.
170. Hoving S, et al. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 2006 17 : 949 959.
171. Millan CG, Marinero ML, Castaneda AZ, Lanao JM. Drug, Enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004 95 : 27 49.
172. Dumez H, et al. In vitro partition of irinotecan (CPT-11) in human volunteer Blood: the influence of concentration, gender and smoking. Anticancer Drugs 2005 16 : 893 895.
173. Wildiers H, et al. Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. Int J Cancer 2002 99 : 514 519.
174. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000 85 : 967 972.
175. Beretz A, et al. Modulation by cytokines of leukocyte-endothelial cell interactions. Implications for thrombosis. Biorheology 1990 27 : 455 460.
176. Magueresse-Battistoni B, Pernod G, Kolodie L, Morera AM, Benahmed M. Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rat testicular peritubular cells. Endocrinology 1997 138 : 1097 1105.
177. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood 1997 89 : 541 549.
178. Clauss M, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990 172 : 1535 1545.
179. van der Poll T, et al. Tumor necrosis factor induces von Willebrand
180. Renard N, et al. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995 176 : 279 287.
181. Renard N, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (RTNF alpha). Int J Cancer 1994 57 : 656 663.
182. Nooijen PTGA, et al. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a vlinical and histopathological study of the delayed-type reaction pattern. Cancer Res 1998 58 : 4880 4887.
183. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006 6 : 6 22.
184. Manusama ER, et al. Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res 1998 78 : 169 175.
185. Ruegg C, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998 4 : 408 414.